Development of Novel Radiosensitizers through the National Cancer Institute's Small Business Innovation Research Program.

ABSTRACT: While radiosensitizing chemotherapy has improved survival for several types of cancer, current chemoradiation regimens remain ineffective for many patients and have substantial toxicities. Given the strong need for the development of novel radiosensitizers to further improve patient outcomes, the Radiation Research Program (RRP) and the Small Business Innovation Research (SBIR) in the National Cancer Institute (NCI) issued a Request for Proposals (RFP) through the NCI SBIR Development Center's contracts pathway. We sought to determine the research outcomes for the NCI SBIR Development Center's funded proposals for the development of radiosensitizers. We identified SBIR-funded contracts and grants for the development of radiosensitizers from 2009 to 2018 using the National Institutes of Hea

SUBMITTER: Zakeri K 

PROVIDER: S-EPMC7266046 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature